NCT06953466View on ClinicalTrials.gov

Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

July 30, 2026

Study Completion Date

July 30, 2026

Conditions
Netherton Syndrome
Interventions
DRUG

QRX003, 4% Lotion

QRX003 Topical Lotion containing 4% active drug (serine protease inhibitor)

Trial Locations (1)

60611

RECRUITING

Northwestern Memorial Hospital, Chicago

Sponsors
All Listed Sponsors
lead

Quoin Pharmaceuticals

INDUSTRY

NCT06953466 - Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome | Biotech Hunter | Biotech Hunter